Wexford Capital
VC Fund
Greenwich, United States
Wexford Capital is an investment advisor which boasts $6.5 billion of assets under management. According to its website, it manages a series of hedge and private equity funds. It is based on Greenwich, CT.
- Total investments:
- 17
- Last investment:
- Lead investor:
- 29%
Last updated:
For AI agents: llms.txt
Industries Wexford Capital invests in
Stages Wexford Capital invests in
Countries Wexford Capital invests in
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Akiba Leisman
|
|||
James Rubin
|
|||
John Doyle
|
|||
John Sites
|
|||
Joseph Jacobs
|
|||
| See all 8 contacts → | |||
Investment Focus
Industry
- Health Care 6 (35%)
- Biotechnology 6 (35%)
- Medical Device 6 (35%)
- Medical 4 (24%)
- Therapeutics 4 (24%)
Stage
- Series C 5 (29%)
- Series B 4 (24%)
- Post-IPO Equity 3 (18%)
- Post-IPO Debt 2 (12%)
- Seed 1 (6%)
Country
- United States 12 (71%)
- Canada 2 (12%)
- Israel 1 (6%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
|
Akiba Leisman
Consultant
|
Consultant | Total investments: 0 | Find email | |
|
James Rubin
Partner
|
Partner | Total investments: 0 | Find email | |
|
John Doyle
Partner
|
Partner | Total investments: 4 | Find email | |
|
John Sites
Partner
|
Partner | Total investments: 0 | Find email | |
|
Joseph Jacobs
President & Co-Founder
|
President & Co-Founder | Total investments: 0 | Find email | |
| See all 8 team members → | ||||
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Bonterra Resources
|
Bonterra is a Canadian gold exploration company with a large balanced portfolio of exploration and mining assets. Bonterra controls the only permitted gold mill in the region with a large land position of approximately 35,000 hectares in the Urban Barry Camp. Bonterra is located in the mining-friendly province of Quebec, within the AbitibiGreenstone Belt.The company was founded in 2007 by Johnny Oliveira. | $3.6M / Post-IPO Debt / Mar 23, 2026 | |
Solitario Zinc
|
Solitario Zinc is an exploration and development company. They provide services that include zinc exploration and development and gold exploration and development. They provide products for commercial use. | $4.5M / Post-IPO Equity / Jun 20, 2025 | |
Sailfish Royalty
|
Sailfish is a yield-focused royalty company. Sailfish owns the TZ Royalty, which is a 3.5% royalty on revenues derived from the sale of gold on Eldorado Gold Corp.’s advanced stage Tocantinzinho gold project, and also holds a gold stream agreement on the San Albino gold project in Northern Nicaragua. | $198.8K / Post-IPO Equity / Dec 03, 2024 | |
Shape Memory Medical
|
Shape Memory Medical Inc is a medical device company based in Santa Clara, California, founded to commercialize innovative medical devices based on Shape Memory Polymer (SMP) materials that were developed at Texas A&M University and Lawrence Livermore National Laboratory. The company is dedicated to developing innovative therapeutic solutionsfor peripheral vascular, cardiovascular, and neurovascular markets.Shape Memory Medical's device is the first to introduce an FDA-cleared medical device utilizing shape memory polymer (SMP) technology to a vascular market, enabling physicians to improve patient care. The Shape Memory Medical team has extensive experience with the SMP foam technology and the commercialization of medical devices. | $38M / Series C / Mar 04, 2024 | |
Mammoth Energy Services
|
Mammoth is an integrated, growth-oriented oilfield service company serving companies engaged in the exploration and development of North American onshore unconventional oil and natural gas reserves. | $120M / Post-IPO Debt / Oct 16, 2023 | |
|
Bonterra Resources
|
Bonterra is a Canadian gold exploration company with a large balanced portfolio of exploration and mining assets. Bonterra controls the only permitted gold mill in the region with a large land position of approximately 35,000 hectares in the Urban Barry Camp. Bonterra is located in the mining-friendly province of Quebec, within the AbitibiGreenstone Belt.The company was founded in 2007 by Johnny Oliveira. | $11M / Post-IPO Equity / Dec 15, 2020 | |
Viseon
|
Viseon is a privately held medical device company committed to developing proprietary technology for use in Minimally Invasive Spine Surgery (MISS) procedures. Viseon has progressed rapidly over the past 6-months, having developed a unique array of devices to improve the procedural and clinical outcomes of many minimally invasive spine surgeryprocedures. In addition to rapid product development of its initial products, Viseon has assembled a world-class Scientific Advisory Board of leading MISS physicians, amassed 13 patents to solidify its intellectual property platform, and completed a series of pre-clinical studies supporting initial human-use, scheduled to begin soon.Viseon was founded in early 2017 as a spin-out from Rebound Therapeutics Corporation. | $18M / Series B / Feb 25, 2020 | |
|
Viseon
|
Viseon is a privately held medical device company committed to developing proprietary technology for use in Minimally Invasive Spine Surgery (MISS) procedures. Viseon has progressed rapidly over the past 6-months, having developed a unique array of devices to improve the procedural and clinical outcomes of many minimally invasive spine surgeryprocedures. In addition to rapid product development of its initial products, Viseon has assembled a world-class Scientific Advisory Board of leading MISS physicians, amassed 13 patents to solidify its intellectual property platform, and completed a series of pre-clinical studies supporting initial human-use, scheduled to begin soon.Viseon was founded in early 2017 as a spin-out from Rebound Therapeutics Corporation. | $5M / Series A / Sep 26, 2017 | |
Rebound Therapeutics
|
Rebound has progressed rapidly over the past 18 months, having developed a unique array of devices to improve the procedural and clinical outcomes of many minimally invasive surgical procedures. In addition to rapid product development of its initial products, Rebound has assembled a world-class Scientific Advisory Board of leading MIS physicians,filed 14 patents to solidify its intellectual property platform and completed a series of pre-clinical studies supporting initial human-use, scheduled to begin soon. | $16.5M / Series B / Jul 25, 2017 | |
ElMindA
|
ElMindA vision is to bring a paradigm change to the management of brain disorders and injuries, by transforming state of the art neuroscience into bed-side clinical practice. ElMindA has developed the BNA™ technology platform, which for the first time allows high resolution visualization and evaluation of the complex neuro-physiologicalinterconnections of the human brain at work, capturing information on the composition, connectivity, synchronization and operation of brain networks. | $28M / Series C / Nov 16, 2015 | |
| See all 17 investments → | |||
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Recommended lists
FAQ
What does Wexford Capital invest in?
Wexford Capital invests primarily in Health Care, Biotechnology and Medical Device startups, most often at Series C and Series B stage. Most of the 17 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact Wexford Capital?
Public channels for Wexford Capital include LinkedIn and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at Wexford Capital?
The team at Wexford Capital includes Akiba Leisman (Consultant), James Rubin (Partner) and John Doyle (Partner), among 8 team members tracked by Shizune. The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
